- Home
- CLLS vs GLO Comparison
CLLS vs GLO Comparison
Compare CLLS & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | GLO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 242.9M |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CLLS | GLO |
|---|---|---|
| Price | $3.55 | $5.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 39.0K | ★ 119.1K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $4.52 |
| 52 Week High | $5.48 | $6.09 |
Technical Indicators
Market Signals| Indicator | CLLS | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 55.73 |
| Support Level | $3.39 | $5.58 |
| Resistance Level | $3.83 | $5.81 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 92.42 | 92.68 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.